Amedisys Inc

Amedisys — Q4 2016 Earnings Presentation

19 slides from Amedisys's earnings presentation, Feb 28, 2017

  1. Slide 1: Amedisys 4Q16 Earnings Call Supplemental Materials

    Amedisys 4Q16 Earnings Call Supplemental Materials March 1, 2017 Exhibit 99.2

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and u

  3. Slide 3: What Investors Want: Themes for 2017

    Post 1Q’17, HCHB disruption should no longer impact operations HCHB 2.0 training will focus on optimization of the platform aimed at driving improved clinical outcomes and additional margin improvement Work on HCHB back office scale opportunities Home Health: Coming out of 2016 HCHB implementation,

  4. Slide 4: Highlights and Summary Financial Results (Adjusted) – 4Q and Year End 2016

    Highlights and Summary Financial Results (Adjusted) – 4Q 2016 and Year End 2016 (1) Amedisys Consolidated Revenue Growth: +8% EBITDA: $31M EBITDA Margin: 8.4% EPS: $0.44 Amedisys Highlights Same Store Admissions: Medicare FFS: +2% Total Episodic: +4% Non-Episodic: (9%) Other Statistics: Medicare rec

  5. Slide 5: Home Health and Hospice Segment (Adjusted) – 4Q 2016 and Year End 2016

    Home Health and Hospice Segment (Adjusted) – 4Q 2016 and Year End 2016 (1) Medicare same store admissions growth positive for 4Q16 (+2%); revenue mix holding steady (76% Medicare FFS) Non-Medicare per visit admissions declined 9% during 4Q16 compared to prior year CPV increase anticipated due to pla

  6. Slide 6: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,2) Highlights Year over year total G&A as a percentage of revenue decreased 150 basis points despite inclusion of roughly $8M related to acquisitions Home health segment G&A: 10 bps y/y increase as % of revenue; mainly driven acquired G&A from Infinity

  7. Slide 7: Amedisys Strategy: Four Areas of Focus

    Amedisys Strategy: Four Areas of Focus Updated 4Q 2016 Clinicians Patient Health Clinicians Patient Health Outstanding Outcomes for Our Patients In Their Homes Amedisys Care Centers & Clinical Teams Current: HCHB implementation complete (disruption roll off by 2/28) Tracking towards full achievement

  8. Slide 8: How We're Tracking

    How We’re Tracking Clinical Distinction Employer of Choice Operational Excellence & Efficiency Driving Growth Outstanding Outcomes for Our Patients In Their Homes Care Centers & Clinical Teams Status Category Update Ongoing Initiative STARS Amedisys achieves a 4-Star average in the April 2017 HHC re

  9. Slide 9: Clinical Distinction: Improvements in Stars

    Clinical Distinction: Improvements in Stars Value Based Purchasing QPC Star Average PS Star Average Amedisys VBP State Avg 4.03 3.67 Large Cohort VBP Comp Avg1 3.53 3.54 Performance in VBP States Relative to Industry Internal analysis suggests that we will be a net receiver of funds in 2018 Metric O

  10. Slide 10: Becoming Employer of Choice: Improving Return on Human Capital

    Becoming Employer of Choice: Improving Return on Human Capital Total voluntary turnover continues to decline, achieving year end 2016 goal of 22.0% Full-time clinician turnover (who are accountable for 83% of total visits) has dropped to 18% Implementing proprietary productivity tool to maximize vis

  11. Slide 11: Operational Excellence: Roadmap to EBITDA Improvement

    Efficiencies and Disruption ($M) Operational Excellence: Roadmap to EBITDA Improvement All patients officially on HCHB Jan. 1. Disruption costs have been deeper than originally estimated but contained and return to normal 60-90 days post-implementation. Tracking towards projected $46M annualized sav

  12. Slide 12: Cost Per Visit Components

    $83.46 $79.24 Components 4Q’15 4Q’16 Variance Detail Mitigation Plan Salaries $60.41 $62.94 $2.53 $1.93 driven by salary increases $0.14 HCHB disruption due to Admin/OT $0.46 clinician mix Expect normal levels post HCHB. Will reduce disruption recedes Initiative focused on optimizing clinician mix (

  13. Slide 13: Driving Top Line Growth: Positive Metrics Across Business Segments

    Driving Top Line Growth: Positive Metrics Across Business Segments We continue to grow across all lines of business 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes * Includes 3,792 (Q1), 3,958 (Q2) 3,608 (Q3), and 3,569 (Q4) completed episodes from Infinity acquisition

  14. Slide 14: Massachusetts: Integrated Post-Acute Home Care Model

    We have expanded our Personal Care segment state wide in Massachusetts overlapping with our strong Home Health and Hospice operations. With the acquisition of Home Staff from Fallon Health in February 2017, we now have a strategic partner that we can pilot with to expand the types of patients we see

  15. Slide 15: Management Team

    Management Team Post HCHB implementation, our team has evolved adding bench strength in execution and operations, and deep Home Health and Hospice experience New Management Adds Retiring in April Chris Gerard COO Start Date: Jan 2017 20+ years of home health and hospice experience Formerly VP of Sou

  16. Slide 16: CMS Update: Home Health and Hospice Reimbursement

    CMS Update: Home Health and Hospice Reimbursement Home Health Medicare Reimbursement FY16 FY17 Final Market basket update 2.3% 2.8% Productivity adjustment (0.4%) (0.3%) Rebasing (2.4%) (2.3%) Nominal case-mix adjustment (0.9%) (0.9%) Net impact – Industry (1.4%) (0.7%) Case mix reweighting / Other

  17. Slide 17: Debt and Liquidity Metrics

    Debt and Liquidity Metrics Net debt defined as total debt outstanding ($96M) less cash balance ($30M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($110M). Liquidity defined as the sum of cash balance and available revolving line of credit. Despite deplo

  18. Slide 18: Adjusted EBITDA to Free Cash Flow Reconciliation

    Adjusted EBITDA to Free Cash Flow Reconciliation (1,2) The financial results for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016, and December 31, 2016 and year ended December 31, 2016 are adjusted for certain items and should be considered a non-GAAP financial measur

  19. Slide 19: Income Statement Adjustments

    Income Statement Adjustments (1) The financial results for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016, December 31, 2016, and year-ended December 31, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of th

Amedisys — Q4 2016 Earnings Presentation on 6ix